JP6968094B2 - ヘテロアリール置換されたピリジン類及び使用方法 - Google Patents

ヘテロアリール置換されたピリジン類及び使用方法 Download PDF

Info

Publication number
JP6968094B2
JP6968094B2 JP2018552704A JP2018552704A JP6968094B2 JP 6968094 B2 JP6968094 B2 JP 6968094B2 JP 2018552704 A JP2018552704 A JP 2018552704A JP 2018552704 A JP2018552704 A JP 2018552704A JP 6968094 B2 JP6968094 B2 JP 6968094B2
Authority
JP
Japan
Prior art keywords
formula
substituted
sulfonyl
amino
trifluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517455A5 (enExample
JP2019517455A (ja
Inventor
アルテンバック，ロバート・ジェイ
ボグダン，アンドリュー
コーチ，ジュバンニ・ペトル・ディウニス
コワート，マーロン・ディー
グレスツラー，スティーブン・エヌ
ケルグテルマンス，ハンス
キム，フィリップ・アール
ファン・デル・プラス，スティーブン・エミエル
ワン，シュエチン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2019517455A publication Critical patent/JP2019517455A/ja
Publication of JP2019517455A5 publication Critical patent/JP2019517455A5/ja
Priority to JP2021173679A priority Critical patent/JP7392211B2/ja
Application granted granted Critical
Publication of JP6968094B2 publication Critical patent/JP6968094B2/ja
Priority to JP2023049450A priority patent/JP7622122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018552704A 2016-06-03 2017-05-24 ヘテロアリール置換されたピリジン類及び使用方法 Active JP6968094B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021173679A JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法
JP2023049450A JP7622122B2 (ja) 2016-06-03 2023-03-27 ヘテロアリール置換されたピリジン類及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03
US62/345,315 2016-06-03
PCT/IB2017/053068 WO2017208115A1 (en) 2016-06-03 2017-05-24 Heteroaryl substituted pyridines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021173679A Division JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法

Publications (3)

Publication Number Publication Date
JP2019517455A JP2019517455A (ja) 2019-06-24
JP2019517455A5 JP2019517455A5 (enExample) 2020-06-25
JP6968094B2 true JP6968094B2 (ja) 2021-11-17

Family

ID=59014678

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552704A Active JP6968094B2 (ja) 2016-06-03 2017-05-24 ヘテロアリール置換されたピリジン類及び使用方法
JP2021173679A Active JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法
JP2023049450A Active JP7622122B2 (ja) 2016-06-03 2023-03-27 ヘテロアリール置換されたピリジン類及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021173679A Active JP7392211B2 (ja) 2016-06-03 2021-10-25 ヘテロアリール置換されたピリジン類及び使用方法
JP2023049450A Active JP7622122B2 (ja) 2016-06-03 2023-03-27 ヘテロアリール置換されたピリジン類及び使用方法

Country Status (35)

Country Link
US (2) US10138227B2 (enExample)
EP (1) EP3464282B1 (enExample)
JP (3) JP6968094B2 (enExample)
KR (2) KR102469995B1 (enExample)
CN (2) CN114671864B (enExample)
AR (2) AR108672A1 (enExample)
AU (3) AU2017273215B2 (enExample)
CA (1) CA3022216A1 (enExample)
CL (1) CL2018003323A1 (enExample)
CO (1) CO2018012171A2 (enExample)
CR (1) CR20180547A (enExample)
CY (1) CY1124031T1 (enExample)
DK (1) DK3464282T3 (enExample)
DO (1) DOP2018000257A (enExample)
EC (1) ECSP18094790A (enExample)
ES (1) ES2806873T3 (enExample)
HR (1) HRP20201068T1 (enExample)
HU (1) HUE050248T2 (enExample)
IL (3) IL303196B2 (enExample)
LT (1) LT3464282T (enExample)
MX (2) MX385054B (enExample)
MY (1) MY199604A (enExample)
PE (1) PE20190511A1 (enExample)
PH (1) PH12018502534B1 (enExample)
PL (1) PL3464282T3 (enExample)
PT (1) PT3464282T (enExample)
RS (1) RS60574B1 (enExample)
RU (2) RU2756743C2 (enExample)
SG (1) SG11201808842VA (enExample)
SI (1) SI3464282T1 (enExample)
SM (1) SMT202000394T1 (enExample)
TW (4) TWI752961B (enExample)
UY (2) UY37272A (enExample)
WO (1) WO2017208115A1 (enExample)
ZA (1) ZA201808423B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022009448A (ja) * 2016-06-03 2022-01-14 アッヴィ・エス・ア・エール・エル ヘテロアリール置換されたピリジン類及び使用方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
JOP20190042B1 (ar) 2016-09-30 2021-08-17 Vertex Pharma مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
HRP20201946T1 (hr) 2016-12-09 2021-01-22 Vertex Pharmaceuticals Incorporated Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora
EP3558982A1 (en) 2016-12-20 2019-10-30 AbbVie S.À.R.L. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
IL276662B (en) 2018-02-15 2022-08-01 Vertex Pharma Macrocycles as modulators of the cystic fibrosis transmembrane conductance regulator, their pharmaceutical compounds, their use in the treatment of cystic fibrosis, and a process for their preparation.
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
KR20220064366A (ko) 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
BR112022009185A2 (pt) * 2019-11-12 2022-07-26 Genzyme Corp Heteroarilaminossulfonamidas de 5 membros para tratar afecções mediadas por atividade de cftr deficiente
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
WO2022125826A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2022150174A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
IL309501A (en) 2021-08-19 2024-02-01 Syngenta Crop Protection Ag Method for controlling pests resistant to diamide and compounds therefor
CA3267795A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd MACROCYCLICAL CFTR MODULATORS
WO2024056791A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414037B2 (en) * 2004-03-30 2008-08-19 The Regents Of The University Of California Hydrazide-containing CFTR inhibitor compounds and uses thereof
EP1765347A4 (en) 2004-06-04 2008-10-01 Univ California COMPOUNDS INVOLVED IN ACCELERATION OF ION TRANSPORT BY MUTANT CFTR AND USES THEREOF
RS53895B1 (sr) 2004-06-24 2015-08-31 Vertex Pharmaceuticals Incorporated Modulatori atp-vezujućih kasetnih transportera
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
JP2010523579A (ja) * 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス Ｃｆｔｒ阻害剤化合物およびそれらの使用
ES2548292T3 (es) 2007-05-25 2015-10-15 Vertex Pharmaceuticals Incorporated Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
WO2009076593A1 (en) 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
AR074060A1 (es) * 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
MX2011004374A (es) 2008-10-23 2011-05-23 Vertex Pharma Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida.
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012048181A1 (en) 2010-10-08 2012-04-12 N30 Pharmaceuticals, Llc Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
CN103946221B (zh) * 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2760463B1 (en) 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
CA3122383A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
US9133210B2 (en) 2013-08-08 2015-09-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
CA2942387A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr actvity
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
SG11201703391VA (en) 2014-10-31 2017-05-30 Abbvie S À R L Substituted chromanes and method of use
US9567322B2 (en) 2014-10-31 2017-02-14 Abbvie S.Á.R.L. Substituted tetrahydropyrans and method of use
EP3277647A1 (en) * 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
HK1253581A1 (zh) * 2015-06-02 2019-06-21 Abbvie S.A.R.L. 经取代的吡啶及使用方法
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
US9796711B2 (en) 2015-10-09 2017-10-24 Abbvie S.Á.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use
NZ741223A (en) 2015-10-09 2023-03-31 Galapagos Nv N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
AU2017256172A1 (en) 2016-04-26 2018-09-06 AbbVie S.à.r.l. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022009448A (ja) * 2016-06-03 2022-01-14 アッヴィ・エス・ア・エール・エル ヘテロアリール置換されたピリジン類及び使用方法
JP7392211B2 (ja) 2016-06-03 2023-12-06 アッヴィ・グローバル・エンタープライザズ・リミテッド ヘテロアリール置換されたピリジン類及び使用方法
JP2023172889A (ja) * 2016-06-03 2023-12-06 アッヴィ・グローバル・エンタープライザズ・リミテッド ヘテロアリール置換されたピリジン類及び使用方法
JP7622122B2 (ja) 2016-06-03 2025-01-27 アッヴィ・グローバル・エンタープライザズ・リミテッド ヘテロアリール置換されたピリジン類及び使用方法

Also Published As

Publication number Publication date
AR108672A1 (es) 2018-09-12
AU2024202468A1 (en) 2024-05-02
RU2021127810A (ru) 2021-10-25
JP7622122B2 (ja) 2025-01-27
KR20220162806A (ko) 2022-12-08
LT3464282T (lt) 2020-09-10
CR20180547A (es) 2019-10-30
EP3464282B1 (en) 2020-04-22
CN109311864B (zh) 2022-05-10
RU2018138707A3 (enExample) 2020-08-24
IL262415B (en) 2021-12-01
IL303196B1 (en) 2024-12-01
JP7392211B2 (ja) 2023-12-06
UY37272A (es) 2018-01-02
MX385054B (es) 2025-03-14
RU2018138707A (ru) 2020-07-14
EP3464282A1 (en) 2019-04-10
TW202515560A (zh) 2025-04-16
JP2019517455A (ja) 2019-06-24
SI3464282T1 (sl) 2020-12-31
DK3464282T3 (da) 2020-07-27
IL303196A (en) 2023-07-01
SMT202000394T1 (it) 2020-09-10
PH12018502534A1 (en) 2019-10-21
MX2021009322A (es) 2021-09-08
PT3464282T (pt) 2020-07-17
JP2022009448A (ja) 2022-01-14
BR112018074815A2 (pt) 2019-03-19
US20170349576A1 (en) 2017-12-07
AU2021282409A1 (en) 2021-12-23
TW202329959A (zh) 2023-08-01
MY199604A (en) 2023-11-08
CO2018012171A2 (es) 2018-11-30
CA3022216A1 (en) 2017-12-07
IL288243B2 (en) 2023-11-01
CN114671864B (zh) 2025-04-08
NZ788542A (en) 2025-06-27
TWI752961B (zh) 2022-01-21
CN109311864A (zh) 2019-02-05
SG11201808842VA (en) 2018-11-29
DOP2018000257A (es) 2018-12-31
US20190055229A1 (en) 2019-02-21
MX2018014758A (es) 2019-04-29
HUE050248T2 (hu) 2020-12-28
US10604515B2 (en) 2020-03-31
PL3464282T3 (pl) 2020-12-14
TWI797926B (zh) 2023-04-01
TW201802085A (zh) 2018-01-16
IL288243A (en) 2022-01-01
US10138227B2 (en) 2018-11-27
AU2017273215B2 (en) 2021-09-09
RU2756743C2 (ru) 2021-10-05
HRP20201068T1 (hr) 2020-11-13
TWI849782B (zh) 2024-07-21
UY40612A (es) 2024-02-15
ZA201808423B (en) 2019-08-28
PE20190511A1 (es) 2019-04-10
CY1124031T1 (el) 2022-03-24
WO2017208115A1 (en) 2017-12-07
ES2806873T3 (es) 2021-02-18
AU2017273215A1 (en) 2018-10-25
KR102719916B1 (ko) 2024-10-23
RS60574B1 (sr) 2020-08-31
AU2021282409B2 (en) 2024-01-18
KR20190015215A (ko) 2019-02-13
NZ747222A (en) 2025-06-27
JP2023172889A (ja) 2023-12-06
IL288243B1 (en) 2023-07-01
IL262415A (en) 2018-12-31
PH12018502534B1 (en) 2020-09-23
AR124916A2 (es) 2023-05-17
KR102469995B1 (ko) 2022-11-24
CN114671864A (zh) 2022-06-28
TW202214614A (zh) 2022-04-16
IL303196B2 (en) 2025-04-01
CL2018003323A1 (es) 2019-03-22
ECSP18094790A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
JP6968094B2 (ja) ヘテロアリール置換されたピリジン類及び使用方法
TWI649325B (zh) 用於治療囊狀纖維化之新穎化合物及其醫藥組合物
JP6779992B2 (ja) Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
JP7025556B2 (ja) Ｐｒｃ２阻害剤
HK40006841B (en) Heteroaryl substituted pyridines and methods of use
HK40006841A (en) Heteroaryl substituted pyridines and methods of use
BR122024019066A2 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística
BR112018074815B1 (pt) Composto de piridina substituída com heteroarila
HK1192227B (en) Thiazolopyrimidine compounds
HK1192227A1 (zh) 噻唑并嘧啶化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211026

R150 Certificate of patent or registration of utility model

Ref document number: 6968094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250